Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Susanne J. Goldie, M.D.

Co-Author

This page shows the publications co-authored by Susanne Goldie and Kenneth Freedberg.
Connection Strength

3.088
  1. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med. 2006 Sep 14; 355(11):1141-53.
    View in: PubMed
    Score: 0.339
  2. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med. 2003 Dec 01; 115(8):632-41.
    View in: PubMed
    Score: 0.279
  3. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002 Apr 22; 162(8):921-8.
    View in: PubMed
    Score: 0.250
  4. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 Mar 15; 344(11):824-31.
    View in: PubMed
    Score: 0.231
  5. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med. 1999 Jan 19; 130(2):97-107.
    View in: PubMed
    Score: 0.199
  6. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med. 2007 Oct; 8(7):439-50.
    View in: PubMed
    Score: 0.091
  7. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med. 2007 Mar; 120(3):272-9.
    View in: PubMed
    Score: 0.087
  8. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Dec 01; 43 Suppl 1:S113-8.
    View in: PubMed
    Score: 0.086
  9. Diagnostic tests in HIV management: a review of clinical and laboratory strategies to monitor HIV-infected individuals in developing countries. Bull World Health Organ. 2006 Jul; 84(7):581-8.
    View in: PubMed
    Score: 0.084
  10. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire. S Afr Med J. 2006 Jun; 96(6):526-9.
    View in: PubMed
    Score: 0.083
  11. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005 Nov 01; 41(9):1316-23.
    View in: PubMed
    Score: 0.079
  12. A therapeutic HIV vaccine: how good is good enough? Vaccine. 2004 Sep 28; 22(29-30):4044-53.
    View in: PubMed
    Score: 0.074
  13. Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis. Clin Infect Dis. 2003 Jan 01; 36(1):86-96.
    View in: PubMed
    Score: 0.065
  14. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002 Dec; 7(4):257-66.
    View in: PubMed
    Score: 0.065
  15. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med. 2002 Dec 9-23; 162(22):2545-56.
    View in: PubMed
    Score: 0.065
  16. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002 Nov 25; 162(21):2478-86.
    View in: PubMed
    Score: 0.065
  17. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr. 2002 Sep 01; 31(1):27-37.
    View in: PubMed
    Score: 0.064
  18. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr. 2002 Aug 01; 30(4):421-8.
    View in: PubMed
    Score: 0.064
  19. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards. Med Care. 2002 May; 40(5):429-41.
    View in: PubMed
    Score: 0.063
  20. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001 Sep; 91(9):1456-63.
    View in: PubMed
    Score: 0.060
  21. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001 Aug; 111(2):140-9.
    View in: PubMed
    Score: 0.059
  22. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol. 2001 Aug; 30(4):864-71.
    View in: PubMed
    Score: 0.059
  23. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001 Mar 20; 134(6):440-50.
    View in: PubMed
    Score: 0.058
  24. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001 Mar 01; 32(5):783-93.
    View in: PubMed
    Score: 0.058
  25. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000 Jun 01; 108(8):634-41.
    View in: PubMed
    Score: 0.055
  26. Are European-specific guidelines needed for prevention of opportunistic infections in HIV-1? Lancet. 1999 Oct 09; 354(9186):1305-6.
    View in: PubMed
    Score: 0.052
  27. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999 May 19; 281(19):1822-9.
    View in: PubMed
    Score: 0.051
  28. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making. 1998 Apr-Jun; 18(2 Suppl):S93-105.
    View in: PubMed
    Score: 0.047
  29. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Cost Eff Resour Alloc. 2012 Sep 19; 10(1):12.
    View in: PubMed
    Score: 0.032
  30. Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med. 2011 Feb; 12(2):97-108.
    View in: PubMed
    Score: 0.029
  31. Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One. 2010 Sep 09; 5(9).
    View in: PubMed
    Score: 0.028
  32. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
    View in: PubMed
    Score: 0.028
  33. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis. 2008 May 01; 197(9):1324-32.
    View in: PubMed
    Score: 0.024
  34. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS. 2007 May 11; 21(8):973-82.
    View in: PubMed
    Score: 0.022
  35. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12; 19(12):1299-308.
    View in: PubMed
    Score: 0.020
  36. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005 May 01; 39(1):69-77.
    View in: PubMed
    Score: 0.019
  37. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients. Antivir Ther. 2005; 10(1):41-52.
    View in: PubMed
    Score: 0.019
  38. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment. Health Care Financ Rev. 2005; 26(4):67-80.
    View in: PubMed
    Score: 0.019
  39. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making. 2002 Jan-Feb; 22(1):27-38.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.